📰 Biodelivery Sciences News
Page 2 - Biodelivery Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Biodelivery Sciences. Real-time updates on events, politics, business and more.
August 29, 2022
One of the major factors driving market expansion is a huge increase in migraine cases. Also, the market is benefiting from improved reimbursement policies...
July 22, 2022
Of the top 20 firms by lobbying revenue during Q2, only two saw that revenue dip compared with the first three months of this year.
July 22, 2022
Carney will join Airbnb in September as the company’s global head of policy and communications, reporting to co-founder and CEO Brian Chesky.
June 17, 2022
Investegate announcements from Hansa Investment Co, Annual Financial Report
March 24, 2022
/PRNewswire/ -- Verified Market Research recently published a report, "Plasma Protein Therapeutics Market" By Product (Human Serum Protein, Plasma-Derived...
March 24, 2022
- The rising prevalence of autoimmune disorders, immune deficiency disorders, bleeding disorders as well as increasing adoption of plasma protein therapy in neurology and other therapeutic
March 23, 2022
RALEIGH, NC / ACCESSWIRE / March 23, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today provided
March 18, 2022
Brokerages expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI – Get Rating) to announce earnings per share (EPS) of $0.08 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for BioDelivery Sciences International’s earnings. BioDelivery Sciences International posted earnings per share of $0.05 in the same quarter last year, which would […]
March 15, 2022
Wall Street analysts expect that BioDelivery Sciences International, Inc. (NASDAQ:BDSI – Get Rating) will post sales of $41.84 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for BioDelivery Sciences International’s earnings, with estimates ranging from $41.00 million to $42.60 million. BioDelivery Sciences International posted sales of $42.17 million in […]
February 14, 2022
/PRNewswire/ -- Ademi LLP is investigating BioDelivery Sciences (NASDAQ: BDSI) for possible breaches of fiduciary duty and other violations of law in its...